Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141414 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
A Phase 2 study of Epilepsy, Partial, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT00141414: Completed Phase 2 study of Epilepsy, Partial, sponsored by Pfizer.
NCT00141414 is a Phase 2 study of Epilepsy, Partial that has completed, run by Pfizer. The registered enrollment target is 82 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141414, a Phase 2 study of Epilepsy, Partial, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (20)
New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Rochester
- Pfizer Investigational Site - The Bronx
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Stanford
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Plantation
Indiana
- Pfizer Investigational Site - Indianapolis
- Pfizer Investigational Site - Indianapolis
Maryland
- Pfizer Investigational Site - Baltimore
- Pfizer Investigational Site - Baltimore
Ohio
- Pfizer Investigational Site - Cleveland
- Pfizer Investigational Site - Columbus
Arkansas
- Pfizer Investigational Site - Little Rock
Massachusetts
- Pfizer Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1997-11 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00141414 record still lists
NCT00141414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT00141414 names 20 study sites across 12 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00141414 about?
NCT00141414 is a clinical study titled "To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.". To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
What is the current status of trial NCT00141414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 1997-11. Estimated completion is 2005-10.
What conditions does trial NCT00141414 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00141414?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00141414?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141414 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00141414's enrollment target sits among peer trials
82 830th of 2000 higher than 1,167 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia